Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Impact
The implementation of A2811 is expected to enhance patient autonomy in healthcare decisions, particularly concerning the prescription of opioids and substances known for high addiction risks. The bill mandates the Division of Consumer Affairs to establish procedures ensuring the privacy of these indications, which would not be disclosed without patient consent. This is a significant shift in the regulation of prescription monitoring, as it acknowledges the role of patients in managing their health and the recovery process.
Summary
Assembly Bill A2811, introduced by Assemblyman Clinton Calabrese, amends the existing prescription monitoring program in New Jersey to empower patients with greater control over their medication prescriptions. Specifically, the bill allows patients to indicate that they should not be prescribed opioid drugs or other controlled substances with a significant potential for abuse or addiction. This indication can be included in the patient's prescription monitoring information only at their request, thereby facilitating better communication between patients and healthcare providers regarding their treatment preferences.
Contention
There may be potential contention surrounding this bill, especially regarding how healthcare providers will adapt to this new system of patient indications. Proponents argue that allowing patients to opt-out of certain prescriptions will ultimately support recovery and reduce the risk of misuse. However, critics might raise concerns about how this could complicate treatment plans for patients who genuinely need these medications but have concerns regarding addiction. Moreover, establishing clear protocols for how and when these indications are communicated, particularly in emergency situations, will be essential to ensure that patient safety is not compromised.
Same As
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.
Requires hospital and emergency room physicians to consult the prescription monitoring program registry and to notify a patient's prescriber that such patient is being treated for a controlled substance overdose.
Expands definition of personal data to include use of reproductive health care services and prohibits collection of reproductive health care prescription drugs from Prescription Monitoring Program.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.